<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03650140</url>
  </required_header>
  <id_info>
    <org_study_id>Pro20170001180</org_study_id>
    <nct_id>NCT03650140</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of Anthocyanins</brief_title>
  <official_title>PKPD of Anthocyanins After Oral Cherry Juice Concentrate in Gout Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to establish the pharmacokinetic parameters of cherry juice
      concentrate and identify its potential to alter inflammatory markers in gout patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Highly sensitive C-reactive protein (hs-CRP)</measure>
    <time_frame>Maximal change in hs-CRP from baseline through study completion (during the 12 hours after a dose)</time_frame>
    <description>Reduction in hs-CRP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>Through study completion (during the 12 hours after a dose)</time_frame>
    <description>The area under the plasma anthocyanin concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory marker expression</measure>
    <time_frame>Through study completion (during the 12 hours after a dose)</time_frame>
    <description>Fold change in mRNA expression of Nrf2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>Through study completion (during the 12 hours after a dose)</time_frame>
    <description>Peak plasma concentration of anthocyanins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak plasma concentration (Tmax)</measure>
    <time_frame>Through study completion (during the 12 hours after a dose)</time_frame>
    <description>Time to achieve peak plasma anthocyanin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2)</measure>
    <time_frame>Through study completion (during the 12 hours after a dose)</time_frame>
    <description>Plasma anthocyanin half-life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Tart cherry concentrate 60 mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive a single oral dose of 60 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 120 mL dose group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tart cherry concentrate 120 mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive a single oral dose of 120 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 60 mL dose group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tart cherry extract 60 mL</intervention_name>
    <description>Subjects will receive a single 60 mL oral dose of tart cherry extract.</description>
    <arm_group_label>Tart cherry concentrate 120 mL</arm_group_label>
    <arm_group_label>Tart cherry concentrate 60 mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tart cherry extract 120 mL</intervention_name>
    <description>Subjects will receive a single 120 mL oral dose of tart cherry extract.</description>
    <arm_group_label>Tart cherry concentrate 120 mL</arm_group_label>
    <arm_group_label>Tart cherry concentrate 60 mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of gout

        Exclusion Criteria:

          -  Allergy to cherries or cherry products

          -  Any history of malignancy

          -  History of any pancreatic or biliary tract disease

          -  Significant Anemia

          -  History of significant renal (sCr &gt; 1.5 mg/dL)

          -  Hepatic disease (liver enzymes 3 times upper limit of normal)

          -  Any active gastrointestinal condition

          -  History of large bowel resection for any reason

          -  Use of cherry juice concentrate or consumption of cherries within 14 days

          -  Personal or inherited bleeding disorders or currently on anticoagulation

          -  Women of childbearing age not on oral contraceptives

          -  Women who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi Schlesinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers, The State University of New Jersey</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naomi Schlesinger, MD</last_name>
    <phone>732-235-7217</phone>
    <email>schlesna@rwjms.rutgers.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Naomi Schlesinger, MD, Professor of Medicine</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Gout</keyword>
  <keyword>Tart Cherry</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

